Rafael Holdings Targets H2 2026 NDA Submission for Trappsol® Cyclo™ After Phase 3 Completion
RFL sits 49% above its 52-week low of $1.12 on elevated volume (3.3× avg).
Summary
Rafael Holdings reported a Q3 FY2026 net loss of $4.2 million and ended the quarter with $30.5 million in cash. The company announced a significant update for its lead candidate, Trappsol® Cyclo™, with an expected New Drug Application (NDA) submission in the second half of calendar 2026. This follows the 8-K filed yesterday, June 10th, which confirmed the completion of the last patient visit in the pivotal Phase 3 TransportNPC trial. The clear timeline for NDA submission is a critical step towards potential commercialization for this clinical-stage biotechnology company.
At the time of this announcement, RFL was trading at $1.67 on NYSE in the Life Sciences sector, with a market capitalization of approximately $92.6M. The 52-week trading range was $1.12 to $3.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.